Does caffeine affect cardiovascular responses?

Vascular Disease Prevention

Volumn 4, Issue 2, 2007, Pages 155-163

  Bradamante, Silvia ^a,c   Barenghi, Livia ^a   Versari, Silvia ^a   Villa, Alessandro ^a   De Jong, Jan Willem ^b  

^a CNR   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

AMP deaminase; Blood pressure; Coffee; Coronary disease; Ischaemia

Indexed keywords

CAFFEINE; DIPYRIDAMOLE; EPHEDRINE; INSULIN;

ANTIOXIDANT ACTIVITY; ARRHYTHMOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIETARY INTAKE; DRUG METABOLISM; HEART HEMODYNAMICS; HEART MUSCLE PERFUSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 34248228585     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727007780599485     Document Type: Review

References (97)

1. Chou TM, Benowitz NL. Caffeine and coffee: effects on health and cardiovascular disease. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1994; 109: 173-89.
2. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol 1996; 34: 119-29.
3. Conlay LA, Conant JA, deBros F, Wurtman R. Caffeine alters plasma adenosine levels. Nature 1997; 389: 136.
4. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002; 26: 593-604.
5. James JE. Critical review of dietary caffeine and blood pressure: a relationship that should be taken more seriously. Psychosom Med 2004; 66: 63-71.
6. Ranheim T, Halvorsen B. Coffee consumption and human health - beneficial or detrimental? - Mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus. Mol Nutr Food Res 2005; 49: 274-84.
7. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
8. Corti R, Binggeli C, Sudano I, et al. Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content: role of habitual versus nonhabitual drinking. Circulation 2002; 106: 2935-40.
9. Arnaud MJ. The pharmacology of caffeine. Prog Drug Res 1987; 31: 273-313.
10. Caubet MS, Comte B, Brazier JL. Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry: the use of metabolic ratios to assess CYP1A2 activity. J Pharm Biomed Anal 2004; 34: 379-89.
11. Le Guennec JC, Billon B, Pare C. Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. Pediatrics 1985; 76: 834-40.
12. Robertson D, Frolich JC, Carr RK, et al. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 1978; 298: 181-6.
13. Nurminen ML, Niittynen L, Korpela R, Vapaatalo H. Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr 1999; 53: 831-9.
14. Zampelas A, Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am J Clin Nutr 2004; 80: 862-7.
15. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. The J-shaped effect of coffee consumption on the risk of developing acute coronary syndromes: the CARDIO2000 case-control study. J Nutr 2003; 133: 3228-32.
16. Happonen P, Voutilainen S, Salonen JT. Coffee drinking is dose-dependently related to the risk of acute coronary events in middle-aged men. J Nutr 2004; 134: 2381-6.
17. Sondermeijer HP, van Marle AG, Kamen P, Krum H. Acute effects of caffeine on heart rate variability. Am J Cardiol 2002; 90: 906-7.
18. Papamichael CM, Aznaouridis KA, Karatzis EN, et al. Effect of coffee on endothelial function in healthy subjects: the role of caffeine. Clin Sci (Lond) 2005; 109: 55-60.
19. Noordzij M, Uiterwaal CS, Arends LR, et al. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 2005; 23: 921-8.
20. Katan MB, Schouten E. Caffeine and arrhythmia. Am J Clin Nutr 2005; 81: 539-40.
21. Du Y, Melchert HU, Knopf H, et al. Association of serum caffeine concentrations with blood lipids in caffeine-drug users and nonusers - results of German National Health Surveys from 1984 to 1999. Eur J Epidemiol 2005; 20: 311-6.
22. Urgert R, Schulz AG, Katan MB. Effects of cafestol and kahweol from coffee grounds on serum lipids and serum liver enzymes in humans. Am J Clin Nutr 1995; 61: 149-54.
23. Superko RH, Wood PD. Drinking decaffeinated coffee may be harmful to heart health. Circulation Suppl 2005; 112(22): 3852/P4.
24. Urgert R, van Vliet T, Zock PL, Katan MB. Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers. Am J Clin Nutr 2000; 72: 1107-10.
25. Verhoef P, Pasman WJ, van Vliet T, Urgert R, Katan MB. Contribution of caffeine to the homocysteine-raising effect of coffee: a randomized controlled trial in humans. Am J Clin Nutr 2002; 76: 1244-8.
26. Christensen B, Mosdol A, Retterstol L, Landaas S, Thelle DS. Abstention from filtered coffee reduces the concentrations of plasma homocysteine and serum cholesterol - a randomized controlled trial. Am J Clin Nutr 2001; 74: 302-7.
27. de Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54: 599-618.
28. Duffy SJ, Keaney JF, Jr., Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001; 104: 151-6.
29. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Tea consumption and mortality after acute myocardial infarction. Circulation 2002; 105: 2476-81.
30. Hodgson JM, Puddey IB, Croft KD, et al. Acute effects of ingestion of black and green tea on lipoprotein oxidation. Am J Clin Nutr 2000; 71: 1103-7.
31. Kleemola P, Jousilahti P, Pietinen P, Vartiainen E, Tuomilehto J. Coffee consumption and the risk of coronary heart disease and death. Arch Intern Med 2000; 160: 3393-400.
32. Aqel RA, Zoghbi GJ, Trimm JR, Baldwin SA, Iskandrian AE. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. Am J Cardiol 2004; 93: 343-6.
33. White PJ, Nguyen TT. Chronic caffeine treatment causes changes in cardiac adenosine receptor function in rats. Pharmacology 2002; 65: 129-35.
34. Johansson B, Georgiev V, Lindstrom K, Fredholm BB. A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res 1997; 762: 153-64.
35. Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 2003; 285: H1797-818.
36. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 1997; 79: 2-10.
37. Headrick JP, Peart J. A3 adenosine receptor-mediated protection of the ischemic heart. Vascul Pharmacol 2005; 42: 271-9.
38. de Jong JW, de Jonge R, Keijzer E, Bradamante S. The role of adenosine in preconditioning. Pharmacol Ther 2000; 87: 141-9.
39. Varani K, Portaluppi F, Gessi S, et al. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: functional and biochemical aspects. Circulation 2000; 102: 285-9.
40. Varani K, Portaluppi F, Gessi S, et al. Caffeine intake induces an alteration in human neutrophil A2A adenosine receptors. Cell Mol Life Sci 2005; 62: 2350-8.
41. Fernandez MJ, Lopez A, Santa-Maria A. Apoptosis induced by different doses of caffeine on Chinese hamster ovary cells. J Appl Toxicol 2003; 23: 221-4.
42. Devasagayam TP, Kamat JP, Mohan H, Kesavan PC. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta 1996; 1282: 63-70.
43. Lee C. Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. Clin Chim Acta 2000; 295: 141-54.
44. Kramer GL, Wells JN. Effects of phosphodiesterase inhibitors on cyclic nucleotide levels and relaxation of pig coronary arteries. Mol Pharmacol 1979; 16: 813-22.
45. Bradamante S, Piccinini F, Delu C, Janssen M, de Jong JW. NMR evaluation of changes in myocardial high energy metabolism produced by repeated short periods of ischemia. Biochim Biophys Acta 1995; 1243: 1-8.
46. de Jong JW, de Jonge R, Dongiovanni P, Keijzer E, Bradamante S. Does caffeine inhibit cardiac AMP deaminase? Cardiovascular Pharmacotherapy, Proceedings of the International Congress on Cardiovascular Pharmacotherapy, 9th, San Salvador, Brazil 2000; 305-9.
47. Achterberg PW, Harmsen E, de Jong JW. Adenosine deaminase inhibition and myocardial purine release during normoxia and ischaemia. Cardiovasc Res 1985; 19: 593-8.
48. Chen W, Hoerter J, Gueron M. A comparison of AMP degradation in the perfused rat heart during 2-deoxy-D-glucose perfusion and anoxia. Part I: The release of adenosine and inosine. J Mol Cell Cardiol 1996; 28: 2163-74.
49. Chen W, Gueron M. AMP degradation in the perfused rat heart during 2-deoxy-D-glucose perfusion and anoxia. Part II: The determination of the degradation pathways using an adenosine deaminase inhibitor. J Mol Cell Cardiol 1996; 28: 2175-82.
50. Thakkar JK, Janero DR, Yarwood C, Sharif H, Hreniuk D. Isolation and characterization of AMP deaminase from mammalian (rabbit) myocardium. Biochem J 1993; 290 ( Pt 2): 335-41.
51. Bak MI, Ingwall JS. Acidosis during ischemia promotes adenosine triphosphate resynthesis in postischemic rat heart. In vivo regulation of 5′-nucleotidase. J Clin Invest 1994; 93: 40-9.
52. Kang YH, Mallet RT, Bunger R. Coronary autoregulation and purine release in normoxic heart at various cytoplasmic phosphorylation potentials: disparate effects of adenosine. Pflugers Arch 1992; 421: 188-99.
53. Rose'Meyer RB, Headrick JP, Peart JN, et al. Acute but not chronic caffeine impairs functional responses to ischaemia-reperfusion in rat isolated perfused heart. Clin Exp Pharmacol Physiol 2001; 28: 19-24.
54. Houston MC. Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. Prog Cardiovasc Dis 2005; 47: 396-449.
55. Sung BH, Lovallo WR, Whitsett T, Wilson MF. Caffeine elevates blood pressure response to exercise in mild hypertensive men. Am J Hypertens 1995; 8: 1184-8.
56. Daniels JW, Mole PA, Shaffrath JD, Stebbins CL. Effects of caffeine on blood pressure, heart rate, and forearm blood flow during dynamic leg exercise. J Appl Physiol 1998; 85: 154-9.
57. Mahmud A, Feely J. Acute effect of caffeine on arterial stiffness and aortic pressure waveform. Hypertension 2001; 38: 227-31.
58. Vlachopoulos C, Panagiotakos D, Ioakeimidis N, Dima I, Stefanadis C. Chronic coffee consumption has a detrimental effect on aortic stiffness and wave reflections. Am J Clin Nutr 2005; 81: 1307-12.
59. Vlachopoulos C, Kosmopoulou F, Panagiotakos D, et al. Smoking and caffeine have a synergistic detrimental effect on aortic stiffness and wave reflections. J Am Coll Cardiol 2004; 44: 1911-7.
60. Papaioannou TG, Karatzi K, Karatzis E, Papamichael C, Lekakis JP. Acute effects of caffeine on arterial stiffness, wave reflections, and central aortic pressures. Am J Hypertens 2005; 18: 129-36.
61. Jee SH, He J, Whelton PK, Suh I, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999; 33: 647-52.
62. Lane JD, Pieper CF, Phillips-Bute BG, Bryant JE, Kuhn CM. Caffeine affects cardiovascular and neuroendocrine activation at work and home. Psychosom Med 2002; 64: 595-603.
63. Hartley TR, Lovallo WR, Whitsett TL. Cardiovascular effects of caffeine in men and women. Am J Cardiol 2004; 93: 1022-6.
64. Savoca MR, Evans CD, Wilson ME, Harshfield GA, Ludwig DA. The association of caffeinated beverages with blood pressure in adolescents. Arch Pediatr Adolesc Med 2004; 158: 473-7.
65. Waring WS, Goudsmit J, Marwick J, Webb DJ, Maxwell SR. Acute caffeine intake influences central more than peripheral blood pressure in young adults. Am J Hypertens 2003; 16: 919-24.
66. Debrah K, Haigh R, Sherwin R, Murphy J, Kerr D. Effect of acute and chronic caffeine use on the cerebrovascular, cardiovascular and hormonal responses to orthostasis in healthy volunteers. Clin Sci (Lond) 1995; 89: 475-80.
67. Watson J, Deary I, Kerr D. Central and peripheral effects of sustained caffeine use: tolerance is incomplete. Br J Clin Pharmacol 2002; 54: 400-6.
68. Lovallo WR, Wilson MF, Vincent AS, et al. Blood pressure response to caffeine shows incomplete tolerance after short-term regular consumption. Hypertension 2004; 43: 760-5.
69. Balasubramaniam R, Chawla S, Grace AA, Huang CL. Caffeine-induced arrhythmias in murine hearts parallel changes in cellular Ca(2+) homeostasis. Am J Physiol Heart Circ Physiol 2005; 289: H1584-93.
70. Mehta A, Jain AC, Mehta MC, Billie M. Caffeine and cardiac arrhythmias. An experimental study in dogs with review of literature. Acta Cardiol 1997; 52: 273-83.
71. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81: 578-82.
72. Richardson T, Rozkovec A, Thomas P, et al. Influence of caffeine on heart rate variability in patients with long-standing type 1 diabetes. Diabetes Care 2004; 27: 1127-31.
73. Nehlig A, Debry G. Potential genotoxic, mutagenic and antimutagenic effects of coffee: a review. Mutat Res 1994; 317: 145-62.
74. Rivenes SM, Bakerman PR, Miller MB. Intentional caffeine poisoning in an infant. Pediatrics 1997; 99: 736-8.
75. Garriott JC, Simmons LM, Poklis A, Mackell MA. Five cases of fatal overdose from caffeine-containing "look-alike" drugs. J Anal Toxicol 1985; 9: 141-3.
76. Myers MG. Effect of caffeine on blood pressure beyond the laboratory. Hypertension 2004; 43: 724-5.
77. Smits P, Thien T. Effects of adenosine on human coronary arterial circulation. Circulation 1991; 84: 2208-10.
78. Smits P, Corstens FH, Aengevaeren WR, Wackers FJ, Thien T. False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion. J Nucl Med 1991; 32: 1538-41.
79. Majd-Ardekani J, Clowes P, Menash-Bonsu V, Nunan TO. Time for abstention from caffeine before an adenosine myocardial perfusion scan. Nucl Med Commun 2000; 21: 361-4.
80. Zheng XM, Williams RC. Serum caffeine levels after 24-hour abstention: clinical implications on dipyridamole (201)Tl myocardial perfusion imaging. J Nucl Med Technol 2002; 30: 123-7.
81. Howden R, Hanlon PR, Petranka JG, et al. Ephedrine plus caffeine causes age-dependent cardiovascular responses in Fischer 344 rats. Am J Physiol Heart Circ Physiol 2005; 288: H2219-24.
82. Ray S, Phadke S, Patel C, Hackman RM, Stohs S. Short-term and long-term in vivo exposure to an ephedra- and caffeine-containing metabolic nutrition system does not induce cardiotoxicity in B6C3F1 mice. Arch Toxicol 2005; 79: 330-40.
83. Nyska A, Murphy E, Foley JF, et al. Acute hemorrhagic myocardial necrosis and sudden death of rats exposed to a combination of ephedrine and caffeine. Toxicol Sci 2005; 83: 388-96.
84. Csajka C, Haller CA, Benowitz NL, Verotta D. Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. Br J Clin Pharmacol 2005; 59: 335-45.
85. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833-8.
86. Kockler DR, McCarthy MW, Lawson CL. Seizure activity and unresponsiveness after hydroxycut ingestion. Pharmacotherapy 2001; 21: 647-51.
87. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J Clin Psychopharmacol 1997; 17: 437-9.
88. Haller CA, Jacob P, 3rd, Benowitz NL. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther 2004; 75: 259-73.
89. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295: 1135-41.
90. Kobayashi K, Nakajima M, Chiba K, et al. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 1998; 45: 361-8.
91. Labbe L, Abolfathi Z, Robitaille NM, et al. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. Ther Drug Monit 1999; 21: 191-9.
92. Joeres R, Klinker H, Heusler H, Epping J, Richter E. Influence of mexiletine on caffeine elimination. Pharmacol Ther 1987; 33: 163-9.
93. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000; 39: 127-53.
94. Keijzers GB, De Galan BE, Tack CJ, Smits P. Caffeine can decrease insulin sensitivity in humans. Diabetes Care 2002; 25: 364-9.
95. Petrie HJ, Chown SE, Belfie LM, et al. Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. Am J Clin Nutr 2004; 80: 22-8.
96. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005; 294: 97-104.
97. Kerr D, James J. Nutrition, physical activity, and obesity. Lancet 2002; 360: 1249.